Table 1. Characteristics of BM and PBSC... | American Society of Hematology

Table 1.

Characteristics of BM and PBSC Recipients

	BM Recipients (n = 29)	PBSC Recipients (n = 20)	P Value^*
Patient age (yr)	38 (18-67)^†	37 (29-61)^†	.68
Day (after transplant) of the lymphocyte analysis	57 (48-69)^†	55 (45-67)^†	.17
Patient sex (males/females)	12/17 (41%/59%)	13/7 (65%/35%)	.15
Donor sex (males/females)	10/19 (34%/66%)	8/12 (40%/60%)	.77
No. of patients with history of splenectomy	1 (3%)	0 (0%)	1.00
No. of CMV seropositive patients (pretransplant)	17 (59%)	9 (45%)	.25
No. of CMV seropositive donors (pretransplant)	17 (59%)	8 (40%)	.15
No. of patients with grade 2-3 acute GVHD^‡	20 (69%)	17 (85%)	.31
No. of patients treated with a corticosteroidρ at the time of lymphocyte analysis	20 (69%)	16 (80%)	.52
No. of patients receiving CMV-specific CD8 T cells9 before the time of lymphocyte analysis	1 (3%)	2 (10%)	.56
No. of patients treated with ganciclovir at the time of lymphocyte analysis	13 (45%)	6 (30%)	.38
No. of patients treated with intravenous Ig between days 0 and 80	3 (10%)	4 (20%)	.42

	BM Recipients (n = 29)	PBSC Recipients (n = 20)	P Value^*
Patient age (yr)	38 (18-67)^†	37 (29-61)^†	.68
Day (after transplant) of the lymphocyte analysis	57 (48-69)^†	55 (45-67)^†	.17
Patient sex (males/females)	12/17 (41%/59%)	13/7 (65%/35%)	.15
Donor sex (males/females)	10/19 (34%/66%)	8/12 (40%/60%)	.77
No. of patients with history of splenectomy	1 (3%)	0 (0%)	1.00
No. of CMV seropositive patients (pretransplant)	17 (59%)	9 (45%)	.25
No. of CMV seropositive donors (pretransplant)	17 (59%)	8 (40%)	.15
No. of patients with grade 2-3 acute GVHD^‡	20 (69%)	17 (85%)	.31
No. of patients treated with a corticosteroidρ at the time of lymphocyte analysis	20 (69%)	16 (80%)	.52
No. of patients receiving CMV-specific CD8 T cells9 before the time of lymphocyte analysis	1 (3%)	2 (10%)	.56
No. of patients treated with ganciclovir at the time of lymphocyte analysis	13 (45%)	6 (30%)	.38
No. of patients treated with intravenous Ig between days 0 and 80	3 (10%)	4 (20%)	.42

P value for the difference between BM and PBSC recipients; tested by Wilcoxon-Mann-Whitney rank-sum test in the case of ordinal or interval variables and by Fisher exact test in the case of nominal variables.

†

Median (range).

‡

No patient developed grade 4 acute GVHD.

ρ As treatment for acute GVHD.

View Large

This Feature Is Available To Subscribers Only